HLN

NEUTRAL

$9.49 Live

Haleon plc · NYSE

Target $11.81 (+24.5%)

$8.71 52W Range $11.42

HLN Haleon plc - Fundamental Analysis

NEUTRAL

Console Chart News

HLN Stock | Fundamental Analysis & Investment Insights

NYSE • Healthcare • Drug Manufacturers - Specialty & Generic

Current Price Live

$9.49

Analyst Target

$11.81

+24.5% Upside

52W High

$11.42

52W Low

$8.71

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 28, 2026

Market cap

$42.18B

P/E

18.98

ROE

10.3%

Profit margin

15.1%

Debt/Equity

0.52

Dividend yield

2.01%

AI Analysis

AI-powered fundamental assessment

Confidence

80%

Haleon plc presents a stable fundamental profile with a Piotroski F-Score of 6/9 and a current price of $9.49 that sits comfortably between its Graham Number ($7.49) and Intrinsic Value ($14.75). While the company exhibits strong profitability margins and a healthy debt-to-equity ratio of 0.52, it is hampered by stagnant revenue growth (0.60%) and a completely bearish technical trend (0/100). The massive spike in earnings growth (92%) appears decoupled from top-line performance, suggesting efficiency gains rather than market expansion. Overall, the stock is a value-play with limited immediate momentum.

Key Strengths

Strong gross margins at 64.77% and operating margins at 23.17%

Conservative leverage with a Debt/Equity ratio of 0.52

Stable financial health indicated by a Piotroski F-Score of 6/9

Sustainable dividend payout ratio of 37.08%

Significant upside potential relative to intrinsic value ($14.75)

Key Risks

Near-zero revenue growth (0.60% YoY) indicating market saturation or lack of pricing power

Severe bearish technical momentum (Technical Trend: 0/100)

Liquidity concerns with a Quick Ratio of 0.68 and Current Ratio of 0.92

High PEG ratio of 2.50 suggesting overvaluation relative to growth

Weak insider sentiment (40/100)

AI Fair Value Estimate

Based on comprehensive analysis

$11.12

+17.2% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Strong

Value

Future

Past

Health

Dividend

AI Verdict

Stable Value Trap Risk

Key drivers: Strong margins, Stagnant revenue, Bearish technicals, Low debt

Confidence

85%

Value

70/100

Ref P/E 18.98, PEG 2.50, Graham $7.49

Positives

Price is below intrinsic value
P/E is reasonable at 18.98

Watchpoints

PEG ratio is high (2.50)
Trading above Graham Number

Future

45/100

Ref Revenue Growth 0.60%, Earnings Growth 92%

Positives

High earnings growth (92%)

Watchpoints

Revenue growth is nearly flat (0.60%)
Bearish technical trend

Past

60/100

Ref Historical price performance

Positives

Positive 5Y change (+38.2%)

Watchpoints

Negative 1Y change (-5.4%)
Inconsistent earnings surprises

Health

75/100

Ref Piotroski F-Score, Debt/Equity

Positives

Piotroski F-Score 6/9 (Stable)
Low Debt/Equity (0.52)

Watchpoints

Current Ratio < 1.0
Quick Ratio 0.68

Dividend

65/100

Ref Yield 2.01%, Payout 37.08%

Positives

Low payout ratio (37.08%)
Consistent dividend rate

Watchpoints

Low yield (2.01%)

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$9.49

Analyst Target

$11.81

Upside/Downside

+24.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for HLN and closest competitors.

Updated 2026-04-27

Company	5Y	3Y	1Y	6M	1M	1W
HLN Haleon plc Primary	+38.2%	+12.9%	-5.4%	+4.5%	-1.9%	-2.0%
ALNY Alnylam Pharmaceuticals, Inc. Peer	+114.5%	+67.5%	+29.6%	-32.7%	-2.8%	-2.3%
ARGX argenx SE Peer	+120.6%	+95.7%	+20.5%	-7.4%	-16.1%	-2.4%
ALC Alcon Inc. Peer	+8.8%	+9.9%	-9.6%	-12.6%	+0.1%	+1.6%
MDLN Medline Inc. Peer	+15.2%	+15.2%	+15.2%	+15.2%	+13.9%	+7.6%

HLN

Haleon plc

Primary

+38.2%

+12.9%

-5.4%

+4.5%

-1.9%

-2.0%

ALN

Alnylam Pharmaceuticals, Inc.

Peer

+114.5%

+67.5%

+29.6%

-32.7%

-2.8%

-2.3%

ARG

argenx SE

Peer

+120.6%

+95.7%

+20.5%

-7.4%

-16.1%

-2.4%

ALC

Alcon Inc.

Peer

+8.8%

+9.9%

-9.6%

-12.6%

+0.1%

+1.6%

MDL

Medline Inc.

Peer

+15.2%

+13.9%

+7.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

18.98

15.63

2.5

1.9

3.82

8.33

33.5

$42.18B

Profitability

Profit margins and return metrics

Profit Margin 15.11%

Operating Margin 23.17%

Gross Margin 64.77%

ROE 10.27%

ROA 4.67%

Growth

Revenue and earnings growth rates

Revenue Growth +0.6%

Earnings Growth +92.0%

Q/Q Revenue Growth N/A

Q/Q Earnings Growth +86.4%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.52

Moderate

Current Ratio

0.92

Weak

Quick Ratio

0.68

Poor

Cash/Share

$0.15

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2024

Revenue

$2.8B

Gross Margin

55.4%

Op. Margin

12.7%

Net Margin

8.4%

Total Assets

$34.3B

Liabilities

$18.1B

Equity

$16.2B

Debt/Equity

1.12x

Quarterly Earnings History

EPS performance vs analyst estimates

2026-07-30

$N/A

2024-10-31

$0.12

+11.5% surprise

2024-08-01

$0.1

+13.7% surprise

2024-02-29

$0.1

-17.4% surprise

Healthcare Sector Comparison

Comparing HLN against 560 companies in the Healthcare sector (34 bullish, 167 neutral, 359 bearish)

P/E Ratio

18.98

This Stock

75.44

Sector Avg

-74.8% (Discount)

Return on Equity (ROE)

10.27%

This Stock

-88.14%

Sector Avg

-111.7% (Below Avg)

Profit Margin

15.11%

This Stock

-16.28%

Sector Avg

-192.8% (Weaker)

Debt to Equity

0.52

This Stock

2.66

Sector Avg

-80.3% (Less Debt)

Revenue Growth

0.6%

This Stock

124.04%

Sector Avg

-99.5% (Slower)

Current Ratio

0.92

This Stock

4.47

Sector Avg

-79.4% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
HLN Haleon plc	NEUTRAL	$42.18B	18.98	10.3%	15.1%	$9.49
ALNY Alnylam Pharmaceuticals, Inc.	BEARISH	$41.57B	135.09	73.3%	8.4%	$313.41	Compare
ARGX argenx SE	BULLISH	$43.35B	35.74	20.2%	30.4%	$700.45	Compare
ALC Alcon Inc.	NEUTRAL	$39.59B	38.6	4.8%	10.3%	$80.29	Compare
MDLN Medline Inc.	NEUTRAL	$38.33B	33.02	6.5%	4.1%	$47.22	Compare

HLN Haleon plc

NEUTRAL

Mkt Cap

$42.2B

P/E

19.0

ROE

10.3%

Price

$9.49

Compare with HLN

Compare with HLN

Compare with HLN

Compare with HLN

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

BUY

5 analysts

Barclays

2026-01-23

Equal-Weight Overweight

Past News Coverage

Recent headlines mentioning HLN from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

HLN

HLN Haleon plc - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!